A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety & Efficacy of Magrolimab vs Placebo in Combination w/ Venetoclax & Azacitidine in Newly Diagnosed, Previously Untreated Patients w/ AML Who Are Ineligible for Intensive Chemotherapy

Protocol No
GILEAD-GS-US-590-6154-AML
Principal Investigator
Guru Subramanian Guru Murthy
Phase
III
Summary
The purpose of this study is to see if magrolimab in combination with venetoclax and azacitidine is more effective than venetoclax and azacitidine in patients newly diagnosed with AML that are unfit for intensive chemotherapy.
Description
Magrolimab vs Placebo plus Venetoclax and Azacitidine in AML
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL